Locally Advanced Pancreatic AdenocarcinomaPANOVA-3CANCT07319910
Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)
A study testing TTFields, Gemcitabine and Nab paclitaxel in people with Locally Advanced Pancreatic Adenocarcinoma, run by NovoCure GmbH.
Trial summary
The EF-54 program (PANOVA-3CA) is a continued access program for adults with locally advanced pancreatic cancer to access TTFields therapy in combination with gemcitabine and nab-paclitaxel. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Locally Advanced Pancreatic Adenocarcinoma
- What is being tested?
- TTFields, Gemcitabine and Nab paclitaxel
- Type of treatment
- Medical device
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- Adult, Older adult
Who may be able to join
- Age ≥ 22 years
- Histologically or cytologically confirmed de novo pancreatic adenocarcinoma
- Locally advanced, non-metastatic disease
- ECOG performance status of 0-2
- Candidate for treatment with gemcitabine and nab-paclitaxel
- Able to operate the NovoTTF-200T system independently or with caregiver support
Who cannot join
- Prior palliative treatment to the pancreatic tumor
- Other active malignancies within the past 5 years (except certain early-stage cancers)
- Significant uncontrolled medical conditions or infections that would interfere with therapy
- Implantable electronic devices in the torso
- Known severe hypersensitivity to adhesives, hydrogel, or chemotherapy agents
- Pregnancy or breastfeeding
About this study
Official title: Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally Advanced Pancreatic Adenocarcinoma: EF-54/PANOVA-3CA
The EF-54 program (PANOVA-3CA) is a continued access program for adults with locally advanced pancreatic cancer to access TTFields therapy in combination with gemcitabine and nab-paclitaxel. The purpose of the program is to allow eligible patients to have access to TTFields while the NovoTTF-200T system is under FDA review. Safety and device performance will be monitored during routine clinical care.
Read the detailed description
This is a non-comparative continued access program. All enrolled patients who meet eligibility criteria will receive TTFields with gemcitabine and nab-paclitaxel.
Eligible patients are ≥22 years old, have histologically or cytologically confirmed de novo pancreatic adenocarcinoma not amenable to surgical resection and without evidence of distant metastases, an ECOG performance status of 0-2, and are candidates for gemcitabine plus nab-paclitaxel chemotherapy.
Patients will continue TTFields therapy in combination with chemotherapy according to the treating physician's and site's local standard of care until local disease progression is identified. After discontinuation, subsequent care and follow-up are per treating physician's and site's local standard. There is no protocol defined post-treatment assessments mandated.
- Being tested
- TTFields, Gemcitabine, Nab paclitaxel
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TTFieldsDevice
TTFields is a non-invasive locoregional therapy that uses alternating electric fields. TTFields are delivered to the abdomen though adhesive transducer arrays connected to the NovoTTF-200T system.
GemcitabineDrug
per standard of care
Nab paclitaxelDrug
per standard of care
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Locally Advanced Pancreatic AdenocarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- NovoCure GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07319910
- Sponsor's protocol ID
- EF-54
- Acronym
- PANOVA-3CA
- Status last verified
- Dec 2025
- First submitted
- 18 Dec 2025
- Last updated
- 6 Jan 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally Advanced Pancreatic Adenocarcinoma: EF-54/PANOVA-3CA
- ClinicalTrials.gov ID
- NCT07319910
- Acronym / sponsor ID
- PANOVA-3CA / EF-54
- Study type
- Expanded access
- Recruitment status
- Temporarily Not Available
- Lead sponsor
- NovoCure GmbHIndustry (pharma, biotech, devices)
- First posted
- 6 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The EF-54 program (PANOVA-3CA) is a continued access program for adults with locally advanced pancreatic cancer to access TTFields therapy in combination with gemcitabine and nab-paclitaxel. The purpose of the program is to allow eligible patients to have access to TTFields while the NovoTTF-200T system is under FDA review. Safety and device performance will be monitored during routine clinical care.
Detailed description
This is a non-comparative continued access program. All enrolled patients who meet eligibility criteria will receive TTFields with gemcitabine and nab-paclitaxel.
Eligible patients are ≥22 years old, have histologically or cytologically confirmed de novo pancreatic adenocarcinoma not amenable to surgical resection and without evidence of distant metastases, an ECOG performance status of 0-2, and are candidates for gemcitabine plus nab-paclitaxel chemotherapy.
Patients will continue TTFields therapy in combination with chemotherapy according to the treating physician's and site's local standard of care until local disease progression is identified. After discontinuation, subsequent care and follow-up are per treating physician's and site's local standard. There is no protocol defined post-treatment assessments mandated.
Study design
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥ 22 years
- Histologically or cytologically confirmed de novo pancreatic adenocarcinoma
- Locally advanced, non-metastatic disease
- ECOG performance status of 0-2
- Candidate for treatment with gemcitabine and nab-paclitaxel
Key exclusion criteria (6 listed)
- Prior palliative treatment to the pancreatic tumor
- Other active malignancies within the past 5 years (except certain early-stage cancers)
- Significant uncontrolled medical conditions or infections that would interfere with therapy
- Implantable electronic devices in the torso
- Known severe hypersensitivity to adhesives, hydrogel, or chemotherapy agents
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TTFieldsTTFields is a non-invasive locoregional therapy that uses alternating electric fields. TTFields are delivered to the abdomen though adhesive transducer arrays connected to the NovoTTF-200T system. | Device | – |
| Gemcitabineper standard of care | Drug | – |
| Nab paclitaxelper standard of care | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2026.
Related trials for Locally Advanced Pancreatic Adenocarcinoma
RecruitingPhase 1/2
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
RecruitingPhase 1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Solid Tumor, Non-Small-Cell Lung Cancer
Recruiting
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
RecruitingPhase 1
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
Active, not recruiting
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Pancreatic Cancer, Pancreatic Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing TTFields, Gemcitabine and Nab paclitaxel in people with Locally Advanced Pancreatic Adenocarcinoma, run by NovoCure GmbH.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2026.